The pros and cons of a single 'Euro-price' for drugs

PharmacoEconomics

Volumn 13, Issue 3, 1998, Pages 271-276

  Towse, Adrian ^a  

^a Office of Health Economics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG COST; DRUG INDUSTRY; ECONOMIC ASPECT; EUROPE; HEALTH ECONOMICS; NOTE; PRIORITY JOURNAL; SOCIOECONOMICS;

COMMERCE; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EUROPEAN UNION; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION;

EID: 0031889195     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813030-00001     Document Type: Note

References (21)

1. Rovira J. Are national drug expenditure control policies compatible with a single European market? Pharmacoeconomics 1996; 10 Suppl. 2: 4-13
2. Senior I. Is Parallel trade in medicines compatible with the single European market? Pharmacoeconomics 1992; 2 (1): 70-6
3. Round Table (European Commission, Member States and the pharmaceutical industry). Completing the single market. Proceedings of the IMS International Meeting; 1997 Dec 9; Frankfurt
4. Danzon P. Trade and price differentials for pharmaceuticals: policy options. London: Office of Health Economics, 1997
5. UK Department of Health. PPRS report to parliament. London: UK Department of Health, 1996
6. Hale D, Towse A. Value of the pharmaceutical industry to the UK economy. London: Office of Health Economics, 1995
7. Danzon P. The uses and abuses of international price comparisons. In: Helms R, editor. Competitive strategies in the pharmaceutical industry. Washington, DC: American Enterprise Institute, 1996
8. Grabowski H, Vernon J. Returns on new drug introductions in the 1980s. J Health Econ 1994; 13: 383-406
9. US Office of Technology Assessment. Pharmaceutical R & D: costs, risks and rewards. Washington, DC: US Government Printing Office, 1993
10. Directorate Generale for Economic and Financial Affairs. The economics of 1992: European economy no. 35. Brussels: Commission of the European Communities, 1988 Mar
11. Economist Advisory Group. The 'cost of non-Europe' in the pharmaceutical industry: research on the 'cost of non-Europe', basic findings. Vol. 15. Brussels: Commission of the European Communities, 1988
12. Danzon P, Percy A. The effects of price regulation on productivity in pharmaceuticals [working paper]. Philadelphia: The Wharton School, University of Pennsylvania, 1996
13. Danzon P. Trade and price differentials for pharmaceuticals: policy options. London: Office of Health Economics, 1997
14. Drummond M, Jonsson B, Rutten, F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997; 40: 199-215
15. Towse A. Overview. In: Towse A, editor. Guidelines for the economic evaluation of pharmaceuticals: can the UK learn from Australia and Canada? London: Office of Health Economics, 1997
16. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 (4): 473-81
17. Drummond M, Bloom B, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8 (4): 671-82
18. Menzin J, Oster G, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care 1996; 12 (1): 52-61
19. Brittan L. Brittan speech on pharmaceutical pricing [press release]. Brussels: European Commission, 1992 Dec 2
20. Merck v. Primecrown. Hearing on C-267/95 and C-268/95. Before the European Court of Justice. Brussels, 1996 Dec 5
21. Kanavos P. A prospective view on European Pharmaceutical Research and development: policy options to reduce Fragmentation and increase competitiveness. Pharmacoeconomics 1998; 13 (2): 181-90